ChemoCentryx, Inc. (CCXI): Price and Financial Metrics

ChemoCentryx, Inc. (CCXI)

Today's Latest Price: $58.14 USD

2.44 (-4.03%)

Updated Jun 4 1:06pm

Add CCXI to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

CCXI Stock Summary

  • With a price/sales ratio of 110.83, ChemoCentryx Inc has a higher such ratio than 97.71% of stocks in our set.
  • As for revenue growth, note that CCXI's revenue has grown -18.84% over the past 12 months; that beats the revenue growth of just 10.55% of US companies in our set.
  • The volatility of ChemoCentryx Inc's share price is greater than that of 95.99% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to CCXI, based on their financial statements, market capitalization, and price volatility, are PRNB, SYRS, TBIO, MEIP, and RARE.
  • Visit CCXI's SEC page to see the company's official filings. To visit the company's web site, go to
CCXI Daily Price Range
CCXI 52-Week Price Range

CCXI Stock Price Chart More Charts

CCXI Price/Volume Stats

Current price $58.14 52-week high $63.78
Prev. close $60.58 52-week low $6.16
Day low $58.02 Volume 230,122
Day high $61.79 Avg. volume 646,032
50-day MA $51.17 Dividend yield N/A
200-day MA $31.61 Market Cap 3.60B

ChemoCentryx, Inc. (CCXI) Company Bio

ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.

CCXI Latest News Stream

Event/TimeNews Detail
Loading, please wait...

CCXI Latest Social Stream

Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about ChemoCentryx Inc that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses

MOUNTAIN VIEW, Calif., June 03, 2020 -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part.

Yahoo | June 3, 2020

The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO )( announced a collaboration study for razuprotafib in COVID-19 treatment) Aileron Therapeutics Inc (NASDAQ: ALRN ) Arca Biopharma Inc (NASDAQ: ABIO ) ( reacted to its planned foray into COVID-19 treatment) argenx SE – ADR (NASDAQ: ARGX ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) ChemoCentryx Inc (NASDAQ: CCXI ) GENMAB A/S/S ADR (NASDAQ: GMAB )(announced positive topline Phase 3 data for daratumumab in light-chain amyloidosis) Imara Inc NASDAQ: (IMRA) Liquidia Technologies Inc (NASDAQ: LQDA ) Mersana Therapeut...

Benzinga Feeds | May 29, 2020

Top Small Cap Stocks for June 2020

Small cap stocks are listed companies that have market capitalizations typically ranging from $300 million to $2 billion. Since the share prices of these companies can have big fluctuations over a short period of time, companies with market caps of up to $10 billion are also found in the small cap universe. Small cap stocks, as represented by the Russell 2000 Index (RUT), have underperformed the broader market over the past 12 months.

Yahoo | May 29, 2020

The Daily Biotech Pulse: Cumberland's Positive Anti-Bacterial Readout, FDA Nods For Bristol-Myers, Astellas

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE )(announced positive one-year Phase 1/2 study and Phase 2 open-label extension study of pegzilarginase in Arginase 1 Deficiency patients) Allogene Therapeutics Inc (NASDAQ: ALLO ) Altimmune Inc (NASDAQ: ALT ) argenx SE – ADR (NASDAQ: ARGX )( announced positive top-line data from a late-stage study of efgartigimod in patients with generalized Myasthenia Gravis) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN )(gained on sell-side comment on the company being a potential target for Sanofi SA (NASDAQ: SNY ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Castle Bioscien...

Benzinga | May 27, 2020

The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) ADC Therapeutics SA (NYSE: ADCT ) (IPOed May 15) Allogene Therapeutics Inc (NASDAQ: ALLO ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) ChemoCentryx Inc (NASDAQ: CCXI ) Evoke Pharma Inc (NASDAQ: EVOK ) I-Mab ADR (NASDAQ: IMAB ) Imara Inc (NASDAQ: IMRA ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) Syndax Pharmaceuticals Inc (NASDAQ: SNDX ) Translate Bio Inc (NASDAQ: TBIO ) Twist Bioscience Corp (NASDAQ: TWST ) United Therapeutics Corporation (NASDAQ: UTHR ) VBI Vaccines Inc (NASDAQ: VBIV ) Vermillion, Inc. (NASDAQ: VRML ) Zai...

Benzinga | May 20, 2020

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo 6.78%
3-mo 22.87%
6-mo 85.87%
1-year 548.88%
3-year 735.34%
5-year 521.82%
YTD 47.00%
2019 262.51%
2018 83.36%
2017 -19.59%
2016 -8.64%
2015 18.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8387 seconds.